Basket Trial di vaccini a peptide lungo sintetico Neoantigen in pazienti con malignità avanzata
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a Simon-two stage multi-cohort study to assess the safety and efficacy of neoantigen synthetic long peptide vaccines in patients with local or metastatic solid tumors.
- To assess the efficacy of NeoSLP vaccination by investigator assessment of Progression-Free Survival at 12 months (PFS12).
- To assess efficacy of NeoSLP vaccination by assessment of Time to Treatment Failure (TTF).
- To assess efficacy of NeoSLP vaccination by assessment of Overall Survival at 24 months (OS24).
- To investigate the immunogenicity of NeoSLP vaccines by ELISpot assay. 5. To assess the safety and tolerability of NeoSLP vaccines.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
California
-
Beverly Hills, California, Stati Uniti, 90212
- Precision NextGen Oncology & Research Center
-
San Francisco, California, Stati Uniti, 94115
- Quest Clinical Research
-
Santa Monica, California, Stati Uniti, 90403
- Asthra Health
-
-
Florida
-
Miami Beach, Florida, Stati Uniti, 33140
- Mount Sinai Comprehensive Cancer Center
-
-
Missouri
-
Bridgeton, Missouri, Stati Uniti, 63044
- St. Louis Cancer Care
-
-
New York
-
New York, New York, Stati Uniti, 10028
- Anna Gattani MD PC
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Patients must satisfy the following criteria to be enrolled in the protocol:
Main Inclusion Criterion:
Pancreatic
- Patients who have local or metastatic pancreatic adenocarcinoma and have started first line therapy of Folfirinox (physician's choice for any concomitant therapies)
- Patients who have undergone somatic tumor sequencing should consider FDA-approved pan-solid tumor therapies if they harbor an FDA-approved somatic alteration. For example, Entrectinib or Larotrectinib (if NTRK gene fusion- positive), Selpercatinib (if RET gene fusion-positive), Pembrolizumab (if MSI-H, dMMR, or TMB-H[≥10 mut/Mb]), and PARP inhibitors (BRCA mutations).
Glioblastoma
1. Patients who are within 6 months of diagnosis and have detectable disease as determined by investigator assessment at the start of vaccine administration.
Basket
1. Patients with local or metastatic malignancies, limited treatment options, and an estimated 5-year survival of less than 50% are eligible for enrollment in this cohort.
Other Inclusion Criteria:
- >= 12 years of age.
- ECOG performance status ≤ 2 or Karnofsky score of >=70.
- Adequate organ function allowing favorable benefit to risk ratio per the treating physician
- Systemic corticosteroid therapy is permitted provided dosing is no greater than 4 mg per day (dexamethasone or equivalent) on the day of vaccine administration.
- Ability to understand and willingness to sign an IRB approved written informed consent document.
Exclusion Criteria:
- History of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty or known allergy to a component of the neoantigen synthetic long peptide vaccine.
- Intercurrent illness requiring chronic use of medications that may interfere with rescue medications for treatment of vaccine-related anaphylaxis or attenuate immune response to vaccine treatment (immunosuppressive therapies).
- Psychiatric illness or social situations that would limit compliance with study requirements.
- History of pre-existing immunodeficiency disorder or autoimmune condition requiring immunosuppressive therapy that would preclude response to vaccine.
- Females of childbearing potential may participate provided they agree to practice abstinence; and, if heterosexually active, agree to use at least 2 highly effective contraceptive methods throughout the study and for 3 months following the last dose of study drug; and have a negative serum pregnancy test.
- Females of non-childbearing potential must be post-menopausal or have been surgically sterilized.
- Male subjects with a female partner of childbearing potential must agree to practice abstinence or to use a physician-approved contraceptive method throughout the study and for 3 months following the last dose of study drug.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Vaccino sintetico personalizzato con peptidi lunghi
|
Personalized Synthetic Long Peptide Vaccine |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
To assess the efficacy of NeoSLP vaccination by investigator assessment of Progression-Free Survival at 12 months (PFS12).
Lasso di tempo: Until progression or death, assessed up to 12 months post first vaccine administration.
|
Progression-Free Survival at 12 months (PFS12) defined as time from first vaccine administration until disease progression by investigator assessment or death due to any cause. |
Until progression or death, assessed up to 12 months post first vaccine administration.
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
To assess efficacy of NeoSLP vaccination by assessment of Time to Treatment Failure (TTF).
Lasso di tempo: Assessed up to 12 months post first vaccine administration
|
Time to Treatment Failure (TTF) is defined as time from first vaccine administration to discontinuation of treatment due to any reason, including disease progression, treatment toxicity, and death. |
Assessed up to 12 months post first vaccine administration
|
|
To assess efficacy of NeoSLP vaccination by assessment of Overall Survival at 24 months (OS24).
Lasso di tempo: Until death, assessed up to 24 months post first vaccine administration
|
Overall Survival at 24 months (OS24) is the landmark of OS defined as the proportion of patients alive at 24 months. |
Until death, assessed up to 24 months post first vaccine administration
|
|
To assess the safety and tolerability of NeoSLP vaccines.
Lasso di tempo: Assessed up to 60 days from last vaccine administration
|
Adverse Events (AEs) and Severe Adverse Events (SAEs) |
Assessed up to 60 days from last vaccine administration
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
To investigate the immunogenicity of NeoSLP vaccines by ELISpot assay.
Lasso di tempo: Assessed at baseline before first vaccine administration and day 50 post
|
Immune monitoring is defined as the percentage of patients showing an immune response to the vaccine components. |
Assessed at baseline before first vaccine administration and day 50 post
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- JLF-200
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .